A detailed history of Centiva Capital, LP transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Centiva Capital, LP holds 15,635 shares of ADPT stock, worth $87,243. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,635
Holding current value
$87,243
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.37 - $5.12 $52,689 - $80,051
15,635 New
15,635 $80,000
Q1 2024

May 15, 2024

BUY
$2.88 - $4.8 $174,139 - $290,232
60,465 New
60,465 $194,000
Q3 2023

Nov 14, 2023

BUY
$5.07 - $8.44 $114,475 - $190,566
22,579 New
22,579 $123,000
Q2 2021

Aug 16, 2021

SELL
$32.22 - $44.59 $1.04 Million - $1.44 Million
-32,211 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$37.26 - $67.74 $950,875 - $1.73 Million
25,520 Added 381.41%
32,211 $1.3 Million
Q4 2020

Feb 16, 2021

BUY
$45.01 - $65.47 $301,161 - $438,059
6,691 New
6,691 $396,000

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $797M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.